Servier

Servier's Tianjin production base in China is one of the sixteen production bases established globally by the Servier Group. It is also the only Asian production base that supplies innovative drugs to China and some Asian countries while supporting local clinical research. Over the more than two decades since its groundbreaking in 2000, the Tianjin production base has continuously expanded with additional investments—obtaining GMP certification and officially commencing operations in 2002, followed by receiving "Singapore HSA GMP" and "ISO-9001" certifications between 2006 and 2007. Gradually, it completed the construction of a new warehouse, a new QC laboratory building, a pilot-scale production workshop for anti-tumor drugs, and a second formulation workshop. Servier’s Tianjin production base in China has extensive experience in the consistency evaluation of generic drugs and the development of innovative drugs. Not only does it localize the production of Servier's original drugs to meet the needs of Chinese patients in cardiovascular metabolism, venous health, and oncology, but it also provides contract manufacturing services for countries like South Korea and other Asian nations. The Tianjin production base boasts a robust and mature quality management system along with industry-leading equipment, committing to continuously optimizing environmental protection measures and enhancing production efficiency, specialized service quality, and management efficiency. Additionally, the Tianjin production base offers Contract Manufacturing Organization (CMO) services to help clients accelerate project implementation.